Logo

Abbisko Therapeutics Reports the Completion of First Patient Dosing of ABSK061 in P-I (ABSK061-101) Clinical Trial for the Treatment of Solid Tumors

Share this
Abbisko Therapeutics Reports the Completion of First Patient Dosing of ABSK061 in P-I (ABSK061-101) Clinical Trial for the Treatment of Solid Tumors

Abbisko Therapeutics Reports the Completion of First Patient Dosing of ABSK061 in P-I (ABSK061-101) Clinical Trial for the Treatment of Solid Tumors

Shots:

  • The first patient has been dosed in the P-I (ABSK061-101) trial evaluating the safety, tolerability & PK of ABSK061 in patients with advanced solid tumors. The trial is currently being conducted in China & US
  • The trial will determine the RP2D & evaluate preliminary anti-tumor activities. The usage of ABSK061 in non-oncology indications incl. achondroplasia has a great potential to grow in addition to its oncology uses
  • ABSK061 is an orally available, highly potent & selective small-molecule FGFR2/3 inhibitor independently discovered & developed by Abbisko with global IP rights. Multiple other pan-FGFR inhibitors showed clinical efficacy in multiple types of tumor carrying FGFR2/3 alterations & have been approved globally, including China & US

Ref: PRNewswire| Image: Abbisko Therapeutics

Click here to­ read the full press release 

Neha

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions